The immune response generated by implanted materials is referred to as the foreign body response (FBR). As part of the FBR, overproduction of the extracellular matrix (ECM) can result in the formation of a fibrotic capsule around the implant.1 This capsule can disrupt tissue-implant interactions such as those necessary for communication between a nerve cell and an implanted electrode. Control over the FBR and the ability to mitigate encapsulation will ultimately allow next-generation sensors and devices to become possible. Human gene-2 relaxin (H2 relaxin) has exhibited anti-fibrotic activity in vivo.2 A synthetic short-chain soluble peptide derived from the B-chain of relaxin, B7-33, mimics the actions of the native peptide displaying anti-fibrotic action in vivo.3 Here, we present a method for the incorporation of B7-33 into biodegradable polymer coatings that can be applied to medical devices. The coating provides controlled-release of the antifibrotic peptide for at least 60 days as demonstrated in vitro. When applied via an industrial relevant dip-coating method, the coating can reduce fibrotic encapsulation in a subcutaneous mouse model for up to 6 weeks.